Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Overview Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Companies Involved in Therapeutics Development Felicitex Therapeutics Inc ManRos Therapeutics NeuroNascent Inc Pharmasum Therapeutics AS Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Drug Profiles FX-9847 - Drug Profile Product Description Mechanism Of Action R&D Progress NNI-351 - Drug Profile Product Description Mechanism Of Action R&D Progress PST-1100 - Drug Profile Product Description Mechanism Of Action R&D Progress PST-900 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Type 1 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme - Drug Profile Product Description Mechanism Of Action R&D Progress Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Dormant Products Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Discontinued Products Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Product Development Milestones Featured News & Press Releases Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics Mar 20, 2013: BIO5-TGen Collaboration Focused on Drug Development for Alzheimer’s Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Felicitex Therapeutics Inc, H1 2018 Pipeline by ManRos Therapeutics, H1 2018 Pipeline by NeuroNascent Inc, H1 2018 Pipeline by Pharmasum Therapeutics AS, H1 2018 Dormant Projects, H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Molecule Type, H1 2018

Felicitex Therapeutics Inc ManRos Therapeutics NeuroNascent Inc Pharmasum Therapeutics AS